Emma Ronca

The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression

A. Gudkov, R. Johnstone, R. Lock, 2022, Frontiers in Oncology.

Systematic In Vitro Evaluation of a Library of Approved and Pharmacologically Active Compounds for the Identification of Novel Candidate Drugs for KMT2A-Rearranged Leukemia

M. Kavallaris, M. Haber, M. Henderson, 2022, Frontiers in Oncology.

Dual Targeting of Chromatin Stability By The Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Shows Significant Preclinical Efficacy in Neuroblastoma

J. Pettitt, N. Issaeva, A. Gudkov, 2021, Clinical Cancer Research.

FDA-approved disulfiram as a novel treatment for aggressive leukemia

M. Haber, M. Henderson, M. Norris, 2024, Journal of molecular medicine.